When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Câncer de bexiga

Última revisión: 13 Sep 2025
Última actualización: 17 Jan 2025

Resumen

Definición

Анамнез и осмотр

Ключевые диагностические факторы

  • presença de fatores de risco
  • hematúria (visível ou não visível)
Полная информация

Другие диагностические факторы

  • polaciúria
  • disúria
Полная информация

Факторы риска

  • exposição ao tabaco
  • exposição a carcinógenos químicos
  • idade >65 anos
  • radiação pélvica
  • uso de ciclofosfamida
  • Infecção por Schistosoma
  • sexo masculino
  • inflamação crônica da bexiga
  • predisposição genética
  • diabetes mellitus
Полная информация

Диагностические исследования

Исследования, которые показаны в первую очередь

  • urinálise
Полная информация

Исследования, проведение которых нужно рассмотреть

  • cistoscopia
  • citologia da urina
  • urograma por tomografia computadorizada (TC)
  • urograma por ressonância magnética (RM)
  • ultrassonografia renal e vesical
  • Hemograma completo
  • perfil bioquímico (incluindo fosfatase alcalina)
  • radiografia torácica
  • TC abdominal e de pelve
  • ressonância nuclear magnética (RNM) abdominal e pélvica
  • PET-TC com fluordesoxiglucose (FDG)
  • cintilografia óssea
  • biomarcadores urinários
Полная информация

Алгоритм лечения

Острый

tumores não invasivos do músculo

tumores localmente invasivos

doença metastática

Составители

Авторы

Joshua J. Meeks, MD, PhD

Associate Professor of Urology

Northwestern University Feinberg School of Medicine

Chicago

IL

Раскрытие информации

JJM is a consultant for Merck, AstraZeneca, Incyte, Janssen, BMS, UroGen, Prokarium, Imvax, Pfizer, and Seagen/Astellas. He has received research funding from the VHA, NIH, and DoD; compensation for talks/educational courses from the AUA, OncLive, Olympus, and UroToday; and clinical trial support from SWOG, Genentech, Merck, AstraZeneca, and Incyte. JJM holds patents on T1 and TCGA classifiers; these are not currently available for use in clinical practice. JJM is an author of a reference cited in this topic.

David VanderWeele, MD, PhD

Associate Professor, Hematology and Oncology

Northwestern University Feinberg School of Medicine

Chicago

IL

Раскрытие информации

DVW declares that he has received payments from Clovis Oncology, Exelixis, Janssen, and Bayer for advisory boards; research payments from AstraZeneca for clinical trials; payments from Astellas and Myovant for lectures; and payments from Exelixis and AstraZeneca for travel and dinner costs.

​Sarah E. Fenton, MD, PhD

Assistant Professor, Hematology and Oncology

Northwestern University Feinberg School of Medicine

Chicago

IL

Раскрытие информации

SEF declares that she has no competing interests.

Выражение благодарностей

Dr Joshua J. Meeks, Dr David VanderWeele, and Dr Sarah E. Fenton would like to gratefully acknowledge Dr Donald Lamm and Dr Mary Heeley, previous contributors to this topic.

Раскрытие информации

DL is an author of a number of references cited in this topic. MH declares that she has no competing interests.

Рецензенты

Junaid Masood, MBBS, FRCS (Eng), MSc (Urol), FRCS (Urol)

Consultant Urological Surgeon

Homerton University Hospital NHS Foundation Trust

London

UK

Раскрытие информации

JM declares that he has no competing interests.

Hugh Mostafid, MD

Consultant Urologist

North Hampshire Hospital

Basingstoke

UK

Раскрытие информации

HM has received honoraria from GE Healthcare and Kyowa Kirin UK.

Thomas Guzzo, MD

Clinical Instructor of Urology

The James Buchanan Brady Urologic Institute

The Johns Hopkins Medical Institutions

Baltimore

MD

Declarações

TG declares that he has no competing interests.

Amir Kaisary, MD, MA, ChM, FRCS

Consultant Urological Surgeon

Honorary Senior Lecturer

Department of Urology

The Royal Free & University College Medical School

London

UK

Declarações

AK declares that he has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

Referências

Nossas equipes internas de editoria e de evidências trabalham em conjunto com colaboradores internacionais especializados e pares revisores para garantir que forneçamos acesso às informações o mais clinicamente relevantes possível.

Principais artigos

American Urological Association. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO joint guideline. 2024 [internet publication].Texto completo

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: bladder cancer [internet publication].Texto completo

European Association of Urology. Non-muscle-invasive bladder cancer. 2023 [internet publication].Texto completo

European Association of Urology. Muscle-invasive and metastatic bladder cancer. 2024 [internet publication].Texto completo

American Urological Association. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. Apr 2024 [internet publication].Texto completo

Artigos de referência

Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.
  • Câncer de bexiga images
  • Diagnósticos diferenciais

    • Hiperplasia prostática benigna (HPB)
    • Cistite hemorrágica
    • Prostatite
    Mais Diagnósticos diferenciais
  • Diretrizes

    • Suspected cancer: recognition and referral
    • Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline
    Mais Diretrizes
  • Patient information

    Câncer de bexiga

    More Patient information
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer